Health
CytoDel Announces Pre-Clinical Data on Cyto-111 as Antidote to Botulinum Neurotoxin (BoNT) Published in Science Translational Medicine – GlobeNewswire
Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection …
Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection
Supports the Development of New Approaches to Treat Multiple Neurological Diseases
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) — CytoDel, Inc. (CytoDel or the Company), a privately-held corporation, today announces the publication of preclinical data on the Companys lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine….
-
General16 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
Business16 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher
-
General18 hours agoToo skewed, too gentlemanly | The Spectator Australia
-
General19 hours agoAlbanese beats drum on economy as trade clouds gather